Equity Overview
Price & Market Data
Price: $3.68
Daily Change: $0.00 / 0.00%
Daily Range: $3.35 - $4.44
Market Cap: $10,506,492
Daily Volume: 378,524
Performance Metrics
1 Week: -8.23%
1 Month: 142.1%
3 Months: 47.79%
6 Months: -20.00%
1 Year: -48.75%
YTD: 47.79%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.